Multilineage hematopoietic reconstitution without clonal selection in ADA-SCID patients treated with stem cell gene therapy.

Gene transfer into HSCs is an effective treatment for SCID, although potentially limited by the risk of insertional mutagenesis. We performed a genome-wide analysis of retroviral vector integrations in genetically corrected HSCs and their multilineage progeny before and up to 47 months after transplantation into 5 patients with adenosine deaminase-deficient SCID. Gene-dense regions, promoters, and transcriptionally active genes were preferred retroviral integrations sites (RISs) both in preinfusion transduced CD34(+) cells and in vivo after gene therapy. The occurrence of insertion sites proximal to protooncogenes or genes controlling cell growth and self renewal, including LMO2, was not associated with clonal selection or expansion in vivo. Clonal analysis of long-term repopulating cell progeny in vivo revealed highly polyclonal T cell populations and shared RISs among multiple lineages, demonstrating the engraftment of multipotent HSCs. These data have important implications for the biology of retroviral vectors, the dynamics of genetically modified HSCs, and the safety of gene therapy.

[1]  N. Copeland,et al.  Gene Therapy Insertional Mutagenesis Insights , 2004, Science.

[2]  B. Kerem,et al.  Fragile sites are preferential targets for integrations of MLV vectors in gene therapy , 2006, Gene Therapy.

[3]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[4]  C. von Kalle,et al.  Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial. , 2005, Blood.

[5]  Takeshi Suzuki,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[6]  A. Fischer,et al.  Gene therapy for severe combined immunodeficiency: are we there yet? , 2007, The Journal of clinical investigation.

[7]  A. Schambach,et al.  Gene therapy: X-SCID transgene leukaemogenicity , 2006, Nature.

[8]  Bruce Aronow,et al.  Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy. , 2007, The Journal of clinical investigation.

[9]  F. Bushman,et al.  Retroviral DNA Integration: ASLV, HIV, and MLV Show Distinct Target Site Preferences , 2004, PLoS biology.

[10]  M. Roncarolo,et al.  Therapeutic applications for hematopoietic stem cell gene transfer , 2002, Nature Immunology.

[11]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[12]  L. Notarangelo,et al.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.

[13]  C. von Kalle,et al.  Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells. , 2005, Blood.

[14]  B. Fehse,et al.  Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. , 2006, Human gene therapy.

[15]  C. Bordignon,et al.  Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Clelia Di Serio,et al.  Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration , 2006, Nature Biotechnology.

[17]  B. Nadel,et al.  V(D)J-mediated Translocations in Lymphoid Neoplasms , 2002, The Journal of experimental medicine.

[18]  Shawn M. Burgess,et al.  Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration , 2003, Science.

[19]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[20]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[21]  Christof von Kalle,et al.  Distinct Genomic Integration of MLV and SIV Vectors in Primate Hematopoietic Stem and Progenitor Cells , 2004, PLoS biology.

[22]  T. Lu,et al.  Unique risk factors for insertional mutagenesis in a mouse model of XSCID gene therapy. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Alessandro Aiuti,et al.  Hot spots of retroviral integration in human CD34+ hematopoietic cells. , 2007, Blood.

[24]  A. Hotz-Wagenblatt,et al.  Insertion of retroviral vectors in NOD/SCID repopulating human peripheral blood progenitor cells occurs preferentially in the vicinity of transcription start regions and in introns. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.

[25]  Christine Kinnon,et al.  Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.

[26]  B. Fehse,et al.  Clonal Dominance of Hematopoietic Stem Cells Triggered by Retroviral Gene Marking , 2005, Science.

[27]  M. Reinders,et al.  Gene therapy: Is IL2RG oncogenic in T-cell development? , 2006, Nature.

[28]  I. Verma,et al.  Gene therapy: Therapeutic gene causing lymphoma , 2006, Nature.

[29]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[30]  N. Copeland,et al.  Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells. , 2005, Blood.

[31]  J. Tisdale,et al.  Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates. , 2000, Blood.

[32]  E. Medico,et al.  Promoter trapping reveals significant differences in integration site selection between MLV and HIV vectors in primary hematopoietic cells. , 2005, Blood.

[33]  T. Rabbitts,et al.  Activation of the T-cell oncogene LMO2 after gene therapy for X-linked severe combined immunodeficiency. , 2004, The New England journal of medicine.

[34]  Sridhar Hannenhalli,et al.  Genome-wide analysis of retroviral DNA integration , 2005, Nature Reviews Microbiology.

[35]  M. Hershfield,et al.  Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy. , 1998, Seminars in hematology.

[36]  B. Aronow,et al.  Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates , 2003, Nature Medicine.

[37]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.